Janssen Pharma Co., Ltd. announced on January 2017, 1 that it will conduct joint research with Fukushima Medical University to develop biomarkers that support the accurate diagnosis of adult ADHD.The research period is planned to be three years until December 6.
The prevalence of ADHD is said to be about 5% in children and about 2.5% in adults.At present, there is no objective diagnostic method, and the diagnosis is based on a combination of symptoms such as hyperactivity and impulsivity.In addition, regarding the diagnosis of adult ADHD patients, it may be difficult to distinguish them from other psychiatric disorders due to symptoms that are also observed in various other psychiatric disorders such as distraction, poor concentration, and difficulty in following tasks. I have problems with both diagnosis and underdiagnosis.Therefore, the development of biomarkers related to the etiology of ADHD is useful for assisting and evaluating the diagnosis of ADHD, and is expected to greatly contribute to future treatment.
Collaborative studies have been reported to be associated with ADHD in adult ADHD patients, ASD patients, and healthy subjects using three methods: dopamine transporter density, mismatch negative potential, and brain network topology using MRI. Consider the difference between them.We aim to establish a biomarker-based diagnostic method that will help in the definitive diagnosis of adult ADHD.
